ClinicalTrials.gg
TerminatedNCT05965505Updated Aug 1, 2024

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

A Phase 1 interventional study of AXT-1003 in Relapsed or Refractory Non-Hodgkin's Lymphoma, sponsored by Axter Therapeutics (Beijing) Co., Ltd. Terminated at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.

Primary conditionLymphoma, Non-HodgkinRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Axter Therapeutics (Beijing) Co., Ltd · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to the adjustment of the protocol and expansion of the indication population, a new clinical trial protocol was submitted to the Health Authority, so the registration was conducted as a new clinical trial and this trial was terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 195 studies in Lymphoma, Non-Hodgkin with a site in China — 82 open to participants now, 109 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Enrollment
182nd of 183
1 · median 58
Started
2023
with 22 others
Phase 1
79 of 195
33 open now
Registered
140th of 195
by date

Among the 195 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 182nd largest by enrollment of the 183 interventional ones that give a count, is one of 23 that started in 2023, is one of 79 in phase 1, and was the 140th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

82 of the 195 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.

Read the detailed description

The study is being conducted to assess the safety, tolerability, and pharmacokinetics (PK) of AXT-1003 in subjects with relapsed/refractory non-Hodgkin lymphomas (R/R NHL) and relapsed/refractory peripheral T-cell lymphoma (R/R PTCL), a subtype of R/R NHL.

03

Conditions studied

  • Relapsed or Refractory Non-Hodgkin's Lymphoma

Browse trials for

Keywords

  • NHL
  • EZH2 inhibitor
  • Phase I
  • Peripheral T-cell Lymphoma
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

This study's enrollment of 1 is below the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Axter Therapeutics (Beijing) Co., Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male subjects aged ≥ 18 years.
  2. Histopathological diagnosis of non-Hodgkin lymphoma [R/R NHL] (except for CLL/SLL), who have progressed after treatment with approved therapies or who have no access to approved or standard therapies.

    Note 1: Refractory is defined as failure to:

    1. Achieve complete response after therapy
    2. Reach at least partial response after second-line therapy or beyond. Note 2: Subjects must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented.
  3. For dose expansion part: Subjects with confirmed R/R NHL by the local pathologist/investigators are enrolled. Most of the enrolled subjects are confirmed with R/R PTCL subtype. Local histological diagnosis will be used for eligibility determination. Subjects with PTCL are eligible according to 2016 World Health Organization (WHO) classification, including but not limited to the following subtypes:

    1. PTCL, not otherwise specified.
    2. Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK) positive
    3. Anaplastic large cell lymphoma, ALK negative
    4. Angioimmunoblastic T-cell lymphoma
    5. Extranodal NK-/T-cell lymphoma, nasal type The subjects enrolled in the dose expansion part should be progressed after treatment with approved therapies or who have no access to approved or standard therapies.
  4. performance status scale 0 to 1.
  5. Have a of at least 3 months.
  6. Have as defined by Lugano 2014 criteria, subjects must have measurable lesions (nodal lesion with any long diameter > 1.5 cm, or extranodal lesion with any long diameter > 1.0 cm) (not mandatory for the dose escalation stage).
  7. Willing to provide archived or fresh tumor tissue samples that are sufficient for EZH2 status detection (not mandatory).
  8. Adequate organ function assessed within 7 days prior to study drug administration.
  9. Bone marrow function: (ANC) ≥ 1.0 × 109/L without growth factor support (filgrastim or) for at least 14 days; ≥ 9.0 g/dL (may receive transfusion), ≥ 75 × 109/L (Evaluated after at least 7 days since last platelet transfusion).
  10. Hepatic function: serum total ≤ 1.5 × (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome; alkaline phosphatase (in the absence of bone disease) /AST ≤ 3.0 × ULN (≤ 5 × ULN if subject has liver ).
  11. Renal function: calculated ≥ 60 mL/min (Cockcroft-Gault method).
  12. Time between prior anticancer therapy and first dose of AXT-1003 as below:

    1. Cytotoxic chemotherapy-at least 21 days or 3.5 half-lives of prior treatment, whichever occurs later.
    2. Non-cytotoxic chemotherapy (eg, small molecule inhibitor)-at least 14 days or 3.5 half-lives of prior treatment, whichever occurs later.
    3. Nitrosoureas-At least 6 weeks or 3.5 half-lives of prior treatment, whichever occurs later.
    4. Monoclonal antibody (ies)-at least 28 days
    5. Radiotherapy-At least 14 days from local site radiation therapy/at least 6 weeks from prior radioisotope therapy/at least 12 weeks from 50% pelvic or total body irradiation.
    6. High dose therapy with autologous hematopoietic cell infusion-at least 60 days.
    7. High dose therapy with transplant-At least 90 days (if [GVHD] is present, must be Grade \< 2) and no prohibited medications.

    Note: Starting at Cycle 1 Day 1, subjects may receive no more than 10 mg of prednisone daily (or equivalent ) when used for treatment of lymphoma related symptoms, with the intent to taper by the end of Cycle 1.

  13. Male subjects must have had a successful vasectomy (with confirmed azoospermia), or they and their female partner must meet the criteria above (ie, not of or practicing highly effective and use a condom throughout the study period and for 3 months after study drug discontinuation). Non-vasectomized male subjects must also agree to refrain from donating sperm from first dose of AXT-1003 until 3 months following the last dose of AXT-1003.
  14. Females must not be lactating or pregnant at screening or baseline (as documented by a negative beta-human chorionic gonadotropin test with a minimum sensitivity of 25 IU/L or equivalent units of beta-human chorionic gonadotropin). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than seven days before the first dose of study drug. All females will be considered as childbearing potential unless they are (at least 12 months consecutively amenorrheic, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing). Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception, from the last menstrual period prior to randomization, during treatment cycles, and for 30 days (will be re estimated after PK profile is known) after the final dose of study drug and have a male partner who uses a condom. Highly effective contraception includes:

    1. Double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide.
    2. Placement of an intrauterine device.
    3. Established hormonal contraceptive methods: oral, injectable, or implant. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation. Female subjects exempt from this requirement if they practice total abstinence or have a male partner who is vasectomized. If currently abstinent, the subject must agree to use a highly effective method of contraception as described above if they become sexually active during the treatment cycles, and for 30 days after study drug discontinuation.
  15. Signed ICF and willing to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of precursor B-cell lymphoblastic leukemia/lymphoma, precursor T-cell lymphoblastic leukemia/lymphoma, precursor NK cell lymphoblastic leukemia/lymphoma.
  2. Diagnosis of CLL, SLL.
  3. Diagnosis of Burkitt lymphoma.
  4. Received treatment with compounds with the same mechanism of action (EZH2 inhibitor, EZH1/EZH2 inhibitor etc.).
  5. Central nervous system infiltration.
  6. or GVHD requiring systemic prophylaxis or treatment.
  7. Uncontrolled or significant cardiovascular disease, including:

    1. Evidence of prolongation of /QTc interval (eg, repeated episodes of QT corrected for heart rate using Fridericia's method > 470 msec) (average of triplicate determinations).
    2. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.
    3. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
    4. Uncontrolled arrhythmia (subjects with asymptomatic, controllable atrial fibrillation may be enrolled) or asymptomatic persistent ventricular tachycardia.
    5. History of second- or third-degree heart block. Subjects with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers within 6 months prior to screening.
    6. Myocardial infarction within 6 months prior to screening.
    7. Angioplasty or stent craft implantation within 6 months prior to screening.
    8. Uncontrolled angina pectoris within 6 months prior to screening.
    9. Class 3 or 4 congestive heart failure.
    10. Coronary/peripheral artery bypass graft within 6 months prior to screening.
    11. Uncontrolled hypertension (resting systolic blood pressure > 160 mmHg or diastolic blood pressure > 110 mmHg).
    12. Complete left bundle branch block.
  8. Venous thrombosis or pulmonary embolism within the last 3 months before starting treatment.
  9. Major surgery within 4 weeks before the first dose of study drug. Note: Minor surgery (e.g, minor of extracranial site, central venous catheter placement, shunt revision) is permitted within 3 weeks prior to enrolment.
  10. Known or suspected to AXT-1003 or any of the .
  11. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of AXT-1003.
  12. Use of known median or potent Cytochrome P450 3A4 () inducers/inhibitors or P glycoprotein (P-gp) inhibitors.
  13. Subjects unwilling to remove seville oranges, grapefruit juice and grapefruit from their diet.
  14. History of other prior to enrolment; except for subjects with basal cell carcinoma of skin, squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinomas in situ who have undergone possible curative treatment and do not have disease recurrence within 5 years since starting the treatment.
  15. Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy, target therapy or other study clinical therapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrolment.
  16. Active infection requiring systemic therapy.
  17. Has known history of chronic infection with virus (hepatitis B surface antigen positive) or virus (detectable antihepatitic C circulating viral RNA).
  18. Immunocompromised subjects, including subjects known to be infected with , and tuberculosis.
  19. Females who are pregnant or breastfeeding.
  20. Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    AXT-1003

    Dose Escalation: Level 1 (Starting Dose) Oral AXT-1003 100 mg BID; Level 2 Oral AXT-1003 200mg BID; Level 3 Oral AXT-1003 300mg BID ; Level 4 Oral AXT-1003 450mg BID; Level 5 Oral AXT-1003 600mg BID; Level 6 Oral AXT-1003 750mg BID Dose Expansion: 1 or 2 cohorts at the dose levels selected from dose escalation part

    Drug: AXT-1003

Interventions

  • AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT) (Dose Escalation)

    Dose Escalation only: to characterize the dose limiting toxicities (DLTs) of AXT-1003.

    Time frame: Up to 28 days

  2. Number of Participants with Adverse Events (AEs) by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness and relationship to study treatment.

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Participants with multiple occurrences of an AE within a category were counted once within the category. Relatedness to study drug was assessed by the investigator.

    Time frame: Baseline up to 30 days after the last dose of study drug

  3. Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

    Laboratory parameters included: hematology, blood chemistry, urinalysis and coagulation. Clinical significance of laboratory parameters was determined at the investigator's discretion.

    Time frame: Baseline up to 30 days after the last dose of study drug

Secondary outcomes

  1. Overall response rates (ORR)

    ORR is defined as the proportion of subjects with a CR or PR.

    Time frame: Up to 3 years

  2. Duration of response(DOR)

    DOR is defined as the time from the initial objective response to progression of disease (PD) or death after the response, whichever occurs first.

    Time frame: Up to 3 years

  3. Progression free survival (PFS)

    Progression-free survival is defined as the time from the first dose of study treatment to the first PD or death for any reason in the absence of documented PD, whichever occurs first

    Time frame: Up to 3 years

  4. Time to response (TTR)

    Time to response is defined as the time from first dose of study treatment to the first objective tumor response.

    Time frame: Up to 3 years

  5. Disease control rate (DCR)

    Disease control rate is defined as the proportion of subjects with a CR, PR, or stable disease(SD).

    Time frame: Up to 3 years

  6. Maximum observed concentration (Cmax) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  7. Time of maximum observed concentration (tmax) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  8. Area under the curve from the time of dosing to the time of the last measurable concentration (AUC0-t) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  9. The partial area from dosing time to dosing time plus Tau (AUC0-tau) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  10. Trough concentration of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 5 months

  11. Minimum observed concentration (Cmin) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  12. Terminal elimination half-life (t1/2) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

  13. Total body clearance (CL/F) of AXT-1003

    Pharmacokinetics of AXT-1003

    Time frame: Up to 15 days

08

Study locations

4 sites
  • Beijing Cancer Hospital
    Beijing, China
  • West China Hospital, Sichuan University
    Chengdu, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Sep 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Jul 28, 2023
StartActual
Aug 11, 2023
Primary completionActual
Sep 5, 2023
CompletionActual
Sep 5, 2023
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05965505
Lead sponsor
Axter Therapeutics (Beijing) Co., Ltd
Responsible party
Sponsor
First posted
Jul 28, 2023
Start date
Aug 11, 2023
Primary completion
Sep 5, 2023
Completion
Sep 5, 2023
Last update
Aug 1, 2024

Study contacts

Yanfang Guo
study director · Axter Therapeutics (Beijing) Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AXT-1003

Start the discussion